We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Xenetic Bio | XEN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.00 | 6.00 |
| Top Posts |
|---|
Posted at 14/9/2016 02:03 by buywell3 ....................Zika vaccine research firm attracts private funding offers after clinching grant 08/09/2016 Private investors are queueing up to fund a small British pharmaceutical company that holds promise of developing the world's first Zika vaccine. Cambridge-based firm Excivion has gained attention since clinching a Government grant worth £500,000 that will help jump-start vaccine development for the mosquito-borne virus. Chief executive and immunologist Peter Laing says he has never seen this kind of interest from private investors during his 22-year career. "I've had people contact me on the website, offering to fund the company. I've never heard of that before, never heard of it in the history of my work in the biotechnology industry," he told the Press Association. Excivion is seeking private backers to keep research going once government funding runs out. The half a million pound grant, issued by the Small Business Research Initiative and Innovate UK, is meant to be spent within 12 months. It is part of the Department of Health's plans to invest up to £10 million in two competitions that would prompt development of vaccines for infectious diseases and technologies. The company is aiming to bring a vaccine to market by 2023, and Excivion staff are working around the clock to develop it. Mr Laing has contracted around 30 scientists across India, the US, Germany and the UK to supplement the company's two-person operation back in Cambridge. This strategy has allowed Mr Laing to recruit the best industry specialists and keep costs down. In mid-August, the company announced a partnership with US-based Nasdaq-listed pharma firm Xenetic Biosciences to develop technologies to deliver the vaccine. Excivion is working with ''micro-encapsulatio "There's a lot of moral pressure to do everything right, and to make sure that you've thought everything through," he said. "It's been been quite stressful actually, because we want to take best advantage of the funding and do right by the British public who ultimately fund this work." Mr Laing and his business partner have put their own money into the company, but he says it is small in comparison. The chief executive is confident Excivion will secure further funding, given the level of interest so far. Mr Laing stopped short of revealing the total number of private offers Excivion has received, but said the company is now eyeing alternative fundraising methods. "In fact we're even considering setting up a parallel charity which would ensure that 100% of those funds could be applied to research and development." There are plans to license the potential Zika vaccine "quite early" to a larger pharmaceutical company that would commit to bringing the product to market. Multiple licenses could be issued in a bid to keep costs low for the countries that need the Zika vaccine most. However, the chief executive made clear that Excivion is not looking for a buy-out. "I want to be a larger company but I don't want to sell the company. I want the company to be in Britain, creating employment, and developing new vaccines." |
Posted at 20/8/2016 00:57 by buywell3 I think the news below , will play well to USA investors in the upcoming Nasdaq floatationZika has the potential to become a Pandemic even in its current form as the mosquitos carrying the virus spread around the world ( now in Florida ) If Zika mutates (or is mutated) with say a bird flu virus ... then we are in even worse trouble The need to produce novel vaccines QUICK that have extended shelf life and can exist in hotter climates WITHOUT fridges ( electricity ) is now critical Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine AUGUST 18, 2016 - Xenetic’s proprietary IMUXEN™ Technology will be used to develop the combined vaccine - LEXINGTON, Mass.-- Xenetic Biosciences, Inc. (OTCQB: XBIO) (“Xenetic̶ Commenting on the collaboration, Scott Maguire, CEO of Xenetic, stated, “We are very pleased to be working with Excivion to develop this important vaccine that will be designed to address these serious pandemic diseases that have spread worldwide. There is a growing sense of urgency for a solution since the unexpected emergence of Zika in Florida, which now represents a real and immediate threat in the United States. The collaboration exploits a new paradigm in rational vaccine design pioneered by Excivion, based on an understanding of the interacting epidemiology of these diseases, with great potential for synergy with Xenetic’s IMUXEN™ vaccine delivery platform. Importantly, this platform enhances the potency of vaccine antigens and provides for cold-chain-free distribution and stockpiling of vaccines for pandemic emergencies.” According to the Centers for Disease Control, Zika and dengue viruses are responsible for a serious burden of morbidity and mortality across the globe. Dengue infection can give rise to a potentially fatal hemorrhagic fever. These concerns were accentuated recently by formal recognition that Zika infection of pregnant women is linked to the occurrence of ‘microcephaly& Commenting on the potential synergy of the IMUXEN™ and antigen-design platforms, Peter Laing, CEO of Excivion, stated, “Xenetic’ |
Posted at 12/11/2015 23:56 by buywell3 If Baxter thought XEN technology worthy of investing their Factor V111 future onPlus the Russian Government putting the future of quite a proportion of their own biotech expansion plans Plus the largest vaccine manufacturer in India also paying for and carrying out clinical trials on a drug which will soon be used across India Then one would imagine USA investors will be wanting in when XEN lists in NASDAQ on the back of further positive clinical trials news plus NEW Orphan drug developments which should ONLY benefit XEN shareholders I would imagine the float price will be in excess of 1.5$ Wonder if the knockers/prats agree ? |
Posted at 17/9/2015 08:14 by buywell3 I will be very surprised if the NASDAQ float does not take place before this xmasThe delay as I understand it is due to some very positive data coming through which will make Xenetic even more attractive to USA investors who want in. This data will need to be included in the prospectus and will make Xenetic an even more compelling investment. The Market Cap of this should exceed $300M on NASDAQ Recent sellers will be somewhat miffed ... is my prediction dyor |
Posted at 12/9/2015 07:49 by buywell2 The delay in the NASDAQ listing I am sure down to Baxter splitting V the prospectus that will have to be written together with a couple of other key issues (data) from two other big investors in XEN becoming available for inclusion.This has been further complicated by SHIRE wanting to now buy Baxalta for $30 BILLION Xenetic have to wait till the deal is done or not done. I think we shall see a listing before this xmas and a subsequent approx fourfold or better increase in the Market Cap of the company depending upon that data . Even better if an EPO deal gets done soon(or at the time of the NASDAQ float) I am now taking a 6 month break from posting dyor |
Posted at 09/9/2015 13:01 by ashthorpedo Saw this nice article by streetinsider about Baxter Investor day in May 2015.The product that is being developed using PolyXen is Bax 826. This product has huge potential as it will be the first Hemophilia A factor replacement therapy to achieve once-weekly therapy. hxxp://www.streetins Cowen maintains a Market Perform rating and $74 price target on Baxter International (NYSE: BAX) following Baxalta investor day. Analyst Joshua Jennings believes that BAX is positioned for sustainable growth, with strong cash flow. Jennings Commented on BAX, saying, "We believe Baxalta is well positioned to deliver 6-8% top-line growth with durable growth assets in the hemophilia and IG franchises, high single-digit operating EPS growth, and an attractive margin profile over the next LRP (2015-2020). To get more positive on the Baxalta story we wanted clarification of a few topics. First, we wanted to see more details on BXLT's capital allocation strategy and sustainability of its cash flows, which were provided at yesterday's investor day and support a balanced approach with an established L&A engine already in place, a dividend payout of 15% in-line with biotech peers, and share repurchases as needed. Second, we wanted to gain further conviction that over the longer-term Baxalta's highly profitable rFVIII franchise could maintain Advate’s leading WW share and that a strategy to mitigate against the potential threat of completely novel approaches for the treatment of hemophilia A/inhibitors entering the market in '18 and beyond was in place. Management provided some comfort by issuing 1-3% annual growth expectations for hemophilia and 5-7% CAGR for inhibitors over the next 5 years. To date, Baxalta has successfully defended its Advate franchise in the U.S. with Eloctate taking only 2% share since launch which we believe bolsters management's credibility after issuing guidance for high single digit U.S. share loss in front of the BAX 855 launch and makes the LRP forecast plausible. The Hemophilia and Inhibitor LRP assumptions incorporates commercialization of late-stage pipeline candidates offsetting competitive headwinds to Advate and Feiba. Expectations for a slow OUS adoption ramp for Eloctate where Advate holds a significant share of the market and where treatment at a significant premium is likely to be met with more resistance are baked in. Management also provided more details around its plans to develop a polysialic derivative of Advate (BAX 826) over the next 2-3 years that has the potential to be the first Hemophilia A factor replacement therapy to achieve once-weekly therapy. This product could be a bridge to what they are positioning as the longterm home run opportunity - gene therapy for hemophilia A with BAX 888 achieving milestones in animal models and on track to enter Phase I in 1Q'16. Third, we wanted Baxalta to demonstrate an ability to be competitive in oncology/hematology and management downloaded the early successes in building out the oncology portfolio. The purchase of OUS rights to MACK's MM-398 for pancreatic/gastric cancer with $400M+ potential, the Oncaspar portfolio immediately bringing $100M+ annually with $200M+ potential by 2020 in ALL alone, and the Phase II asset BAX 555 from AesRx that could fulfill an unmet need in sickle-cell anemia as a prophylaxis treatment is a nice entry point for Baxalta's into the hematology/oncology sectors." |
Posted at 07/9/2015 17:02 by buywell3 It is my bank balance that matters most thoughRe TUNG If you had a brain cell you would see that sometimes I try to help fellow investors in stocks I like from making balls-ups Funnily enough most don't seem to like it like you This chart and a comment that 150p was coming for example Would have been followed by another saying 75p was next But when I get bad-mouthed I let the perp take the fall |
Posted at 28/8/2015 12:28 by trotterstrading I spoke with Scott back in March.. Nasdaq will happen, hopefully Sept/Oct. We just need to get the Rusnano and SII (shareholders) on the same page re the required capital restructure - co-ordinating these two requires patience!The recent uptick in volume must be from US investors buying in, which is great news, means our story is finally getting out there. Sadly I'm locked out, can't buy or sell, I'm guessing it's the same for the majority of UK investors? |
Posted at 13/4/2015 22:31 by ashthorpedo All will become clear very soon. Annual results are due by 15th so we will find out how the fundraising is coming along.In total agreement with you Trotters, Maguire is responsible for this fiasco. If he wasn't aware he should have been aware that european investors would have had a problem dealing on OTC. He has put the blame for the fall in share price on a few investors selling the odd thousand shares knocking the price of the company down by millons but the reality is that there is no buyers in america otherwise the price would not have fallen. He talks endlessly about derisking biotech with testing drugs in Russia and India but we have not seen any results for a long time and by the sound of the last conference call never will. I can't see investors paying much more than the current price unless the money comes from Baxter again or Rusnano. I can see a placing at 25c and Maguire will be saying that he has done a great job getting a 20% premium to the current price. I hope I'm wrong. |
Posted at 28/3/2015 07:37 by buywell2 '' Of the 41 drugs approved by the FDA last year, nine are treatments for cancer, and more than 1,000 targeted cancer treatments are in development, including many with genetic-based indications.With some of those drugs being priced in the mid to high five figures per year, cancer is a significant driver of drug spending, increasing 21 percent last year for Express Scripts. As Bloomberg Business observed of the biotech and pharma boom, investors are betting that $100,000 oncology drug prices are here to stay.'' Scott Maguire, chief executive, told an investors' conference call on Tuesday that the priority remains getting the firm to a size where it can list on the North American Stock Dealers Automated Quotation (NASDAQ) system, though this is still some way off as it is currently worth a quarter of the US$160mln minimum market value for the US market. “We’re at a stage where we need the capital markets to reflect our science, which is good and great,” said Maguire, adding that 2015 is shaping up to be a year of significant milestones for the group. The firm is preparing to enter human clinical trials in the US with its lead product OncoHist in 2015 and has been pitching the treatment to US investors to help fund the trials. “Only time will tell whether OncoHist a game changer for cancer treatment,” said Maquire, adding that it could revolutionise leukaemia therapy. Study identifies genetic cause of increased leukemia risk Friday 27 March 2015 Cancer / Oncology Genetics Blood / Hematology Pediatrics / Children's Health News this week has been chock-full of headlines covering Angelina Jolie's decision to have her ovaries and fallopian tubes removed due to her increased risk of ovarian and breast cancer with the BRCA1 gene mutation. Scientists have now found a gene mutation that similarly increases the risk of acute lymphoblastic leukemia. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
